Context Therapeutics (NASDAQ:CNTX) outlined its pipeline of T-cell engaging bispecific antibodies for solid tumors during a presentation at a Jefferies conference, with management focusing primarily on its lead program, CTIM-76, a Claudin 6 x CD3 bispecific antibody being developed mainly for ovarian cancer.
The company said its three clinical or near-clinical programs are designed to force interaction between T cells and cancer cells, prompting an immune response against tumors. The presenter described T-cell engagers as a still-emerging modality, noting that most approved products to date have been in liquid tumors, though there have been two approvals in solid tumors.
CTIM-76 Data Update Expected Soon
The company is developing CTIM-76 primarily in ovarian cancer, particularly platinum-resistant ovarian cancer. The presenter said the “vast majority” of platinum-resistant ovarian cancer patients express Claudin 6 and tend to express it at high levels, which the company believes may increase the probability of response.
Context said it has enrolled “quite a few” patients in the CTIM-76 study, including about 15 at target dose levels. Roughly 10 of those 15 are platinum-resistant ovarian cancer patients, and the company has previously guided that nearly all are experienced with antibody-drug conjugates, or ADCs.
The company said the ongoing study began with lower projected subtherapeutic doses before escalating into what it considered active dose ranges. It added intermediate cohorts at 210 micrograms and 280 micrograms to increase the number of ovarian cancer patients included in the June dataset.
Prior Update Showed Early Response and Low CRS
Context reviewed its most recent detailed CTIM-76 update, which it said was provided around Halloween and covered dosing through the 280 microgram level for safety and through 140 micrograms for efficacy. At that time, the company reported linear and dose-proportional pharmacokinetics, T-cell movement out of the bloodstream toward the target, and dose-proportional cytokine elevations.
On efficacy, Context said one patient in the 140 microgram cohort had a deep and durable response. According to the presentation, the patient had about a 50% decrease in target lesions at week eight, which deepened to 85% at week 16, and remained on treatment. The company said the patient had previously received multiple ovarian cancer therapies, including mirvetuximab, olaparib, bevacizumab and an experimental therapy.
On safety, Context said that as of the October update, one patient had Grade 1 cytokine release syndrome, with no dose-limiting toxicities and no maximum tolerated dose identified. The presenter attributed the potentially low rate of cytokine release syndrome to Claudin 6’s tumor-restricted profile, steroid prophylaxis and step dosing.
Company Sees Less Frequent Dosing as Strategic
Context said it is exploring every-three-week dosing, or Q3W, for CTIM-76 after being “pleasantly surprised” by the drug’s pharmacokinetic profile. The presenter said that after one week, “there’s still a lot of drug present,” and argued that Q3W dosing could be more convenient for patients while aligning with dosing schedules for ADCs and PD-1/PD-L1 bispecifics.
The company also discussed broader field data suggesting that allowing T-cell engagers to wash out between doses could reduce T-cell exhaustion and potentially improve durability of response. Context said its current profile could allow drug exposure for 10 to 14 days within a 21-day interval, followed by a washout period.
Pipeline Includes Mesothelin and Nectin-4 Programs
Beyond CTIM-76, Context highlighted CT-95, a mesothelin-targeting T-cell engager that entered the clinic last year. The company said it is particularly interested in pancreatic cancer for that program and remains on track to report preliminary data in September.
The company’s newest clinical entrant is CT-202, a Nectin-4-targeting program. Context said Nectin-4 is expressed across a wide range of tumors, including urothelial cancer, colorectal cancer, breast cancer and lung cancer. The company said the Nectin-4 program is expected to have a first patient dosed shortly and could generate clinical data in 2027.
Context described itself as a “search and development company” without in-house research, saying it acquired all three programs. The company said the different antibody formats across the programs reflect target-specific engineering considerations.
Combination Strategy and Cash Runway
Context said its initial development strategy is to use its drugs as monotherapies to address resistance to standard-of-care treatments, which it expects will increasingly include ADCs in solid tumors. Over time, the company said it sees opportunities to combine its T-cell engagers with ADCs and PD-1/VEGF-targeting agents.
The presenter said Context believes ADCs may help debulk tumors and create a more favorable immune microenvironment, while PD-1/VEGF approaches could deepen and prolong T-cell responses. The company said it sees potential partnership opportunities with large pharmaceutical companies pursuing these combinations.
Context also addressed competition in Claudin 6, naming Xencor as another key company in the space. The presenter said Context views itself and Xencor as “breaking from the pack,” while noting that a clearer comparison will require clinical data from both companies.
On financing, Context said it last raised substantial capital in 2024 and has cash into the middle of next year, providing approximately one year of runway.
About Context Therapeutics (NASDAQ:CNTX)
Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.
With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.
